"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

Absci management is scheduled to participate in a fireside chat on Wednesday, February 5 th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived ...

Needham highlighted Absci's distinct approach in the competitive artificial intelligence and machine learning (AI/ML) field, which is crowded with companies offering similar services. The research ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

Equities research analysts at Needham & Company LLC assumed coverage on shares of Absci (NASDAQ:ABSI – Get Free Report) in a ...

Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The stock has shown ...

The Stargate Project, a $500B initiative focused on artificial intelligence, lifted AI-driven biotech stocks this week while boosting an unlikely winner, Metagenomi (NASDAQ:MGX), which benefitted from ...

Absci’s Drug Creation platform relies on proprietary ... and the results also feed back into the AI to continue to train the ML algorithms. The company maintains that the ability to create ...

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech ...